SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-24-003285
Filing Date
2024-01-23
Accepted
2024-01-23 07:46:44
Documents
14
Period of Report
2024-01-18
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20019485_8k.htm   iXBRL 8-K 31816
2 EXHIBIT 10.1 ef20019485_ex10-1.htm EX-10.1 403516
6 image1.jpg GRAPHIC 3405
  Complete submission text file 0001140361-24-003285.txt   614245

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA atai-20240118.xsd EX-101.SCH 3857
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE atai-20240118_lab.xml EX-101.LAB 23291
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atai-20240118_pre.xml EX-101.PRE 16547
8 EXTRACTED XBRL INSTANCE DOCUMENT ef20019485_8k_htm.xml XML 4213
Mailing Address 524 BROADWAY NEW YORK NY 10013
Business Address WALLSTRASSE 16 BERLIN 2M 10179 (617)-699-5876
ATAI Life Sciences N.V. (Filer) CIK: 0001840904 (see all company filings)

IRS No.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40493 | Film No.: 24550493
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)